Clinical Trials Logo

Filter by:
NCT ID: NCT02796677 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

Start date: July 5, 2016
Phase: Phase 3
Study type: Interventional

This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).

NCT ID: NCT02794285 Completed - Clinical trials for Active Systemic Lupus Erythematosus

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

TULIP SLE LTE
Start date: June 30, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.

NCT ID: NCT02792699 Completed - Clinical trials for Arthritis, Rheumatoid

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Start date: May 17, 2016
Phase: Phase 3
Study type: Interventional

This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with moderate or severe RA. This study will also assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine.

NCT ID: NCT02792231 Completed - Clinical trials for Relapsing Multiple Scelrosis

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

ASCLEPIOS II
Start date: August 26, 2016
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

NCT ID: NCT02792218 Completed - Clinical trials for Relapsing Multiple Sclerosis

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

ASCLEPIOS I
Start date: September 20, 2016
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

NCT ID: NCT02788214 Terminated - Gastric Cancer Clinical Trials

Helicobacter Pylori Genome Project (HpGP)

Start date: July 27, 2016
Phase:
Study type: Observational

Helicobacter pylori is a common bacterial infection. It can lead to severe stomach problems, including stomach cancer. Researchers want to look at samples of the bacteria. These H. pylori strains will be taken from chronically infected people. They want to identify the genetic and epigenetic differences in H. pylori strains. This could help predict which people who get infected with the bacteria will get stomach cancer. This could lead to the cancer being detected earlier. It could also mean less people get stomach cancer. Objectives: To study genetic variations of H. pylori strains based on samples from chronically infected people. To identify the features of strains that might lead to severe stomach problems or stomach cancer. Eligibility: People ages 30-70 years who need an upper endoscopy or who were recently diagnosed with stomach cancer Design: Participants will be screened by the doctor who does their procedure and a study nurse. Participants who have endoscopy will have ~6 biopsies removed. These are tissue samples. They are about the size of a grain of rice. Participants will allow the study team to access reports from their stomach exam. Participants with stomach cancer will donate some of the tissue that will be removed during their clinical care. They will allow the study team to access reports of their surgery. They will also allow them to access the microscope slides of their stomach.

NCT ID: NCT02786290 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia

The Zenflow Spring System Feasibility and Safety Study

ZEST
Start date: April 2016
Phase: N/A
Study type: Interventional

This is a First in Human study to assess the feasibility, safety and effectiveness of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).

NCT ID: NCT02784704 Completed - Clinical trials for Complicated Appendicitis

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

IGNITE4
Start date: October 13, 2016
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics (PK) of eravacycline compared with meropenem in the treatment of complicated intra-abdominal infections (cIAIs).

NCT ID: NCT02782858 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

CHANGE-MS
Start date: April 2016
Phase: Phase 2
Study type: Interventional

The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis (MS). This study evaluates the effect on MRI lesions parameters, the safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis.

NCT ID: NCT02782104 Completed - Clinical trials for Depressive Disorder, Treatment-Resistant

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

SUSTAIN-3
Start date: June 9, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).